EX-99.1 3 shire8k071503ex991.txt PRESS RELEASE Q2 2003 RESULTS PRESENTATION - 31 July 2003 Basingstoke, UK - 15 July 2003 - Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce second quarter 2003 earnings on Thursday, 31 July 2003. Results announcement time: 12:00 BST / 07:00 ET Conference call time: 14:00 BST / 09:00 ET Live conference call: The details of the live conference call are as follows: UK dial in + 44 1452 542 304 US / Canada dial in 1866 389 9780 Password Shire Pharmaceuticals Live audio webcast: There will also be a live audio webcast available, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website. Replay: A replay of the presentation will be available for 2 weeks. Details are as follows: ----------------------------------------- ------------------------------------ UK International no: + 44 (0)1452 55 00 00 ----------------------------------------- ------------------------------------ UK PIN (access) no: 321825# ----------------------------------------- ------------------------------------ US no: 1866 276 1167 ----------------------------------------- ------------------------------------ US PIN (access) no: 321825# ----------------------------------------- ------------------------------------ Webcast Replay www.shire.com, in the investor relations section If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894 160 End For further information please contact: Global Investor Relations Clea Rosenfeld +44 (0)1256 894 160 North America Investor Relations Gordon Ngan +44 (0)1256 894 160 Notes to editors Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international emerging pharmaceutical company with a strategic focus on four therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and anti-infectives. Shire also has three platform technologies: advanced drug delivery, lead optimisation for small molecules and Biologics. Shire's core strategy is based on research and development combined with in-licensing and a focus on key pharmaceutical markets. For further information on Shire, please visit the Company's website: www.shire.com THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. Statements included herein that are not historical facts, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialise, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialisation, the impact of competitive products, including, but not limited to, the impact on Shire's Attention Deficit Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to, legal challenges relating to Shire's ADHD franchise, government regulation and approval, including but not limited to the expected product approval date of lanthanum carbonate (FOSRENOL(R)) and METHYPATCH (R) , and other risks and uncertainties detailed from time to time in our filings, including the Annual Report filed on Form 10-K by Shire with the Securities and Exchange Commission.